reference/8250962

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8250962

Outgoing Links

Predicate	Object
contentType	Clinical Trial Protocol\|Journal Article
issn	1471-230X
issueIdentifier	1
pageRange	82-
publicationName	BMC Gastroenterology
startingPage	82
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_27b70b8ef56685b6ec8b1bee671f3f82 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_665d7d8b26be61d84f23b5abd7000da9 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_e49c88affd54d19cac9d5492fac7ff91 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_f21504ae75e591602787c9b1da17b2a5
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_883c2805159044ab6350e387f02ca6a5
bibliographicCitation	Aapkes SE, Bernts LHP, van den Berg AP, van den Berg M, Blokzijl H, Cantineau AEP, van Gastel MDA, de Haas RJ, Kappert P, Müller RU, Nevens F, Torra R, Visser A, Drenth JPH, Gansevoort RT. Protocol for a randomized controlled multicenter trial assessing the efficacy of leuprorelin for severe polycystic liver disease: the AGAINST-PLD study. BMC Gastroenterology. 2022 Feb 25;22(1):82. doi: 10.1186/s12876-022-02142-y.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b792ed4501ea0cd8de8517d50511a41e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7b5a33ed5cbb2288b50d39f685a7f912 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_04f5514a4fa307ec4ce028002d36e889 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f86576f5c06395620b7dc7a0c81d1660 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2c802a57e54483be47e02dd62787c9e9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d09a027772fd4a9e5a86c72836670ca0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_750fb94d83c8118b68a9e2452c497fe8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aeeb05a85b628d3b90aa7dc63b1a6cc5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_019d583ed57374b7aac217ee4071d2cb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9abbf57483f04e2fa20e9ad842de3488 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d092d7f8f8f77a442f43701a0ad25b5b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_567412d442a06d9cb179a91d77f843f1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_58a202ead084244efaa3026b2472bc43 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d58512e00e9d17899caff399e2b71054 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_124fb8cb5c50978cff47ad396fb2a525
date	2022-02-25^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC8876117 https://doi.org/10.1186/s12876-022-02142-y https://pubmed.ncbi.nlm.nih.gov/35216547
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21974 https://portal.issn.org/resource/ISSN/1471-230X
language	English
source	https://scigraph.springernature.com/ https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Protocol for a randomized controlled multicenter trial assessing the efficacy of leuprorelin for severe polycystic liver disease: the AGAINST-PLD study
discusses	http://id.nlm.nih.gov/mesh/M0025473 http://id.nlm.nih.gov/mesh/C536330
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D008107Q000188 http://id.nlm.nih.gov/mesh/D016729Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D015337 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D011446 http://id.nlm.nih.gov/mesh/D003560 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D016032
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23676225 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID657181 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_ee295a5c65096dd2c3e94d1c1564b59c http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID1052 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID41198

Showing number of triples: 1 to 53 of 53.